DESTINY-Breast03 Phase 3 Study Results
Quality-of-Life
100
80
60
40
40
20
Global health status
100
80
60
60
40
20
20
Physical functioning
0
0
C1D1
C3D1
C5D1
C8D1
C11D1
C14D1
C17D1
EOT
C1D1
C3D1
C5D1
C8D1
C11D1
C14D1 C17D1
EOT
Responders
Non-Responders
(9/10)
(8/10)
(10/10)
(7/7)
(7/7)
(6/6)
(5/5)
(4/5)
Responders
(9/10)
(8/10)
(10/10)
(7/7)
(7/7)
(6/6)
(5/5)
(5/5)
(2/3)
(3/3)
(2/2)
(1/1)
(1/1)
(0/1)
(0/0)
(1/1)
Non-Responders
(3/3)
(3/3)
(2/2)
(1/1)
(1/1)
(1/1)
(0/0)
(1/1)
100
80
60
40
20
Overall
Responders
Non-responders
Emotional functioning
0
C1D1
C3D1
C5D1
C8D1
C11D1 C14D1 C17D1
EOT
Responders
(9/10)
(8/10)
(10/10)
Non-Responders
(2/3)
(3/3)
(2/2)
(7/7)
(1/1)
(7/7)
(6/6)
(5/5)
(1/1)
(0/1)
(0/0)
(4/5)
(1/1)
Overall
--
Responders
Non-responders
100
80
60
40
20
Overall
-- Responders A Non-responders
Cognitive functioning
0
C1D1
C3D1
C5D1
C8D1 C11D1 C14D1 C17D1
EOT
Responders.
Non-Responders
(9/10)
(8/10)
(10/10)
(7/7)
(7/7)
(6/6)
(5/5)
(4/5)
(2/3)
(3/3)
(2/2)
(1/1)
(1/1)
(0/1)
(0/0)
(1/1)
Overall
Responders
Non-responders
ESMO BC 2022 #165 Mini Oral
QoL was maintained over the treatment period
Daiichi-Sankyo
58View entire presentation